CSIMarket
 
Xoma Corporation  (XOMA)
Other Ticker:  
 
 
Price: $25.1800 $-1.14 -4.331%
Day's High: $26.8299 Week Perf: -1.83 %
Day's Low: $ 25.03 30 Day Perf: 13.53 %
Volume (M): 16 52 Wk High: $ 26.83
Volume (M$): $ 408 52 Wk Avg: $18.21
Open: $26.29 52 Wk Low: $13.48



 Market Capitalization (Millions $) 289
 Shares Outstanding (Millions) 11
 Employees -
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -46
 Cash Flow (TTM) (Millions $) 102
 Capital Exp. (TTM) (Millions $) 0

Xoma Corporation
Xoma Corporation is a biotechnology company that specializes in the research, development, and commercialization of therapeutic antibodies and other technologies for the treatment of various diseases. The company focuses on developing antibody-based therapies for inflammatory and autoimmune disorders, as well as for cancer and infectious diseases. Xoma has a robust pipeline of product candidates and utilizes its proprietary antibody discovery and optimization technologies to advance its research and development efforts. The company aims to bring innovative treatments to patients and improve clinical outcomes across a wide range of medical conditions.


   Company Address: 2200 Powell Street Emeryville 94608 CA
   Company Phone Number: 204-7200   Stock Exchange / Ticker: NASDAQ XOMA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Xoma Corporation

Xoma Corporation's Demand Surges in Fourth Quarter, But Financial Troubles Loom

The recent surge in revenue for the Major Pharmaceutical Preparations company may seem like a positive sign on the surface, but a deeper look at their financials reveals troubling information that should raise red flags for investors. Despite the 23.351% increase in revenue to $1.83 million, the company experienced a significant increase in deficit per share, reaching $-1.86 per share. This sequential increase from $-0.60 per share is a cause for concern, as it indicates that the company is not effectively managing their expenses and may be overspending.
Additionally, the doubling of revenue by 120.843% from the previous reporting period may seem impressive, but it is important to note that this increase was not enough to offset the net deficit of $-25.581 million. This deficit is substantially larger than the $-11.448 million reported in the same period a year ago, indicating that the company is struggling to generate profits and may be operating at a loss.

Merger and Acquisition

XOMA Boosts Therapeutic Portfolio with Kinnate Biopharma Acquisition, Declares Dividends Amid Market Challenges

Published Fri, Feb 16 2024 1:00 PM UTC

XOMA Expands Therapeutic Portfolio with Acquisition of Kinnate Biopharma, Declares Dividends Amidst Stock Challenges
The Xoma Corporation, a leading biopharmaceutical company known for its focus on developing innovative antibody-based therapies, made headlines on September 25, 2023, with two major announcements. Firstly, Xoma entered into an agreement to acquire Kinnate ...

Merger and Acquisition

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition

Published Thu, Jan 18 2024 1:30 PM UTC


XOMA, a leading biotech company in the Major Pharmaceutical Preparations industry, has recently announced a significant non-dilutive royalty capital solution to Talphera worth $8 million. This deal marks another milestone in XOMA's commitment to driving innovation and growth in the pharmaceutical sector.
The biotech giant has a proven track record of providing strat...

Financing Agreement

XOMA's Resilient Spirit Shines Despite Stock Challenges: FDA Approval of Arimoclomol NDA and Cash Dividends Show Commitment to Investors

Published Thu, Jan 11 2024 9:05 PM UTC



In the dynamic world of biotechnology, companies face constant challenges in developing innovative therapies and maintaining a robust stock performance. XOMA Corporation, a biotechnology firm based in Emeryville, California, recently found itself navigating a difficult period with declining stock performance. However, amidst these challenges, XOMA has managed to ma...

Financing Agreement

XOMA Announces Stock Repurchase Program of up to $50 Million, Demonstrating Commitment to Shareholders and Strengthening Capital Structure

Published Tue, Jan 2 2024 12:30 PM UTC


This move by XOMA comes after the company's Leverage Ratio fell to 0.17 due to net new borrowings of 16.69%. Although below the Xoma average Leverage Ratio, it is worth noting that 42 other companies within the industry reported lower Leverage Ratios in the III Quarter of 2023.
Compared to other companies in the industry, XOMA Corporation now ranks higher with a Lev...






 

Xoma's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Xoma does not provide revenue guidance.

Earnings Outlook
Xoma Corporation does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com